CN104837489A - 三环吲哚衍生物的结晶方法 - Google Patents

三环吲哚衍生物的结晶方法 Download PDF

Info

Publication number
CN104837489A
CN104837489A CN201380062872.4A CN201380062872A CN104837489A CN 104837489 A CN104837489 A CN 104837489A CN 201380062872 A CN201380062872 A CN 201380062872A CN 104837489 A CN104837489 A CN 104837489A
Authority
CN
China
Prior art keywords
composition
formula
compound
group
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380062872.4A
Other languages
English (en)
Chinese (zh)
Inventor
S.尼尔森
S.B.A.P.巴拉吉
U.P.莫卡帕蒂
A.M.卡达维帕兰普穆罕默德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1300647.3A external-priority patent/GB201300647D0/en
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Priority to CN202010090283.9A priority Critical patent/CN111362863A/zh
Publication of CN104837489A publication Critical patent/CN104837489A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
CN201380062872.4A 2012-11-30 2013-11-28 三环吲哚衍生物的结晶方法 Pending CN104837489A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010090283.9A CN111362863A (zh) 2012-11-30 2013-11-28 三环吲哚衍生物的结晶方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN3689DE2012 2012-11-30
IN3689/DEL/2012 2012-11-30
GBGB1300647.3A GB201300647D0 (en) 2013-01-15 2013-01-15 Crystallization
GB1300647.3 2013-01-15
PCT/EP2013/074986 WO2014083113A1 (en) 2012-11-30 2013-11-28 Crystallization process of tricyclic indole derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010090283.9A Division CN111362863A (zh) 2012-11-30 2013-11-28 三环吲哚衍生物的结晶方法

Publications (1)

Publication Number Publication Date
CN104837489A true CN104837489A (zh) 2015-08-12

Family

ID=54266915

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380062872.4A Pending CN104837489A (zh) 2012-11-30 2013-11-28 三环吲哚衍生物的结晶方法
CN202010090283.9A Pending CN111362863A (zh) 2012-11-30 2013-11-28 三环吲哚衍生物的结晶方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010090283.9A Pending CN111362863A (zh) 2012-11-30 2013-11-28 三环吲哚衍生物的结晶方法

Country Status (12)

Country Link
US (1) US10709798B2 (cg-RX-API-DMAC7.html)
EP (1) EP2943195A1 (cg-RX-API-DMAC7.html)
JP (1) JP6280560B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150088802A (cg-RX-API-DMAC7.html)
CN (2) CN104837489A (cg-RX-API-DMAC7.html)
AU (1) AU2013351152A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015012138A2 (cg-RX-API-DMAC7.html)
CA (1) CA2892485A1 (cg-RX-API-DMAC7.html)
IN (1) IN2015DN03978A (cg-RX-API-DMAC7.html)
MX (1) MX2015006871A (cg-RX-API-DMAC7.html)
RU (1) RU2015118217A (cg-RX-API-DMAC7.html)
WO (1) WO2014083113A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2015118217A (ru) 2012-11-30 2017-01-11 ДжиИ ХЕЛТКЕР ЛИМИТЕД Способ кристаллизации трициклических индольных производных
US20160144477A1 (en) * 2014-11-21 2016-05-26 Diane Scott Coated compressive subpad for chemical mechanical polishing

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448933A (zh) * 2009-03-27 2012-05-09 通用电气健康护理有限公司 作为pbr配体的吲哚衍生物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177440B1 (en) * 1996-10-30 2001-01-23 Eli Lilly And Company Substituted tricyclics
JP2001522884A (ja) 1997-11-14 2001-11-20 イーライ・リリー・アンド・カンパニー アルツハイマー病の処置方法
DZ2769A1 (fr) 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
JP2005527464A (ja) 2001-08-09 2005-09-15 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビターとしてのシクロヘプタＢインドール誘導体
JP2005527466A (ja) 2001-08-09 2005-09-15 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビターとしてのシクロヘプトＢインドール誘導体
CN102834379B (zh) 2010-03-26 2014-12-24 通用电气健康护理有限公司 作为pbr配体的三环吲哚衍生物
GB201016038D0 (en) 2010-09-24 2010-11-10 Ge Healthcare Ltd In vivo imaging method
GB201016411D0 (en) 2010-09-30 2010-11-10 Ge Healthcare Ltd In vivo imaging method for cancer
GB201021263D0 (en) 2010-12-15 2011-01-26 Ge Healthcare Ltd Solid phase extraction method
US9220795B2 (en) * 2011-09-22 2015-12-29 Ge Healthcare Limited Indole derivatives
RU2015118217A (ru) 2012-11-30 2017-01-11 ДжиИ ХЕЛТКЕР ЛИМИТЕД Способ кристаллизации трициклических индольных производных

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448933A (zh) * 2009-03-27 2012-05-09 通用电气健康护理有限公司 作为pbr配体的吲哚衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HARRY WADSWORTH ET AL: "[18F]GE-180:A novel flurine-18 labelled PET tracer for imaging Translocator protein 18 kDa(TSPO)", 《BIOORGANIC& MEDICINAL CHEMISTRY LETTERS》 *

Also Published As

Publication number Publication date
MX2015006871A (es) 2015-09-16
IN2015DN03978A (cg-RX-API-DMAC7.html) 2015-10-02
US20150335766A1 (en) 2015-11-26
JP2016507477A (ja) 2016-03-10
CN111362863A (zh) 2020-07-03
AU2013351152A1 (en) 2015-05-21
BR112015012138A2 (pt) 2017-07-11
EP2943195A1 (en) 2015-11-18
US10709798B2 (en) 2020-07-14
CA2892485A1 (en) 2014-06-05
JP6280560B2 (ja) 2018-02-14
WO2014083113A1 (en) 2014-06-05
RU2015118217A (ru) 2017-01-11
KR20150088802A (ko) 2015-08-03

Similar Documents

Publication Publication Date Title
RU2468014C2 (ru) Фторсодержащие лиганды для нацеливания периферических бензодиазепиновых рецепторов
CA3160899C (en) Spiro compound serving as erk inhibitor, and application thereof
JP6216421B2 (ja) 造影剤の合成および使用のための組成物、方法およびシステム
TWI915558B (zh) Cot 調節劑及其使用方法
EP4332102A1 (en) Isoquinolone compound and use thereof
KR102137348B1 (ko) 시트레이트 완충제 내 18ｆ―플루시클로빈 조성물
CN101678129B (zh) 用于ccr5体内成像的放射性pet试剂
ES2727158T3 (es) Ligandos para PET de mGluR2 radiomarcados
JP2014040426A (ja) ［５−（４，６−ジメチル−１ｈ−ベンゾイミダゾール−２−イル）−４−メチル−ピリミジン−２−イル］−［３−（１−メチル−ピペリジン−４−イル）−プロピル］−アミンの結晶性ヘミタートレート
US9546167B2 (en) Radiosynthesis of tau radiopharmaceuticals
KR102063498B1 (ko) 불포화 탄화수소기를 갖는 알코올 용매를 이용한 플루오로 화합물의 제조방법
JP6280560B2 (ja) 三環式インドール誘導体の結晶化プロセス
JP6446268B2 (ja) クエン酸緩衝液中の１８ｆ−フルシクロビン組成物
JP5870031B2 (ja) 自動化放射合成
WO2019131458A1 (ja) ２－［５－（イミダゾール－１－イルメチル）ピリジン－３－イル］ベンズイミダゾール誘導体化合物、及び、これを含む医薬
KR101441406B1 (ko) 디아릴이오도늄 염 전구체를 이용한 플로오린-18이 표지된 플루마제닐의 제조 방법
WO2013014274A1 (en) 5ht1a antagonist useful for in vivo imaging
KR101519425B1 (ko) 역류방지 반응용기를 포함하는 카세트를 이용한 방사성 의약품의 제조방법
JP6041751B2 (ja) スチリルピリジン誘導体化合物
JP2014218454A (ja) スチリルピリジン誘導体化合物
TW201204396A (en) Heterocyclic amino acids

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150812

RJ01 Rejection of invention patent application after publication